Loading
A phase 2 trial of Mirdametinib in Advanced melanoma, run by Kevin Kim, MD, now recruiting.
Mirdametinib in Patients With Advanced NF1-mutant Melanoma is a phase 2 interventional study registered as NCT07237100 by Kevin Kim, MD, with 10 participants planned, started 2025-10-13 and due to reach its primary completion in 2027-10-13. Interventions recorded: Mirdametinib. Conditions recorded: Advanced Unresectable Melanoma, Metastatic Melanoma.
Linked to the drug Mirdametinib because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mirdametinib and the tag pipeline.
Shares Mirdametinib and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/